Cargando…
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice
A present challenge in breast oncology research is to identify therapeutical targets which could impact tumor progression. Neurotensin (NTS) and its high affinity receptor (NTSR1) are up regulated in 20% of breast cancers, and NTSR1 overexpression was shown to predict a poor prognosis for 5 year ove...
Autores principales: | Dupouy, Sandra, Doan, Van Kien, Wu, Zherui, Mourra, Najat, Liu, Jin, De Wever, Olivier, Llorca, Frédérique Penault, Cayre, Anne, Kouchkar, Amal, Gompel, Anne, Forgez, Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226680/ https://www.ncbi.nlm.nih.gov/pubmed/25249538 |
Ejemplares similares
-
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib
por: Younes, Mohamad, et al.
Publicado: (2014) -
The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression
por: Dupouy, Sandra, et al.
Publicado: (2009) -
Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy
por: Wu, Zherui, et al.
Publicado: (2013) -
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007) -
Imaging Neurotensin Receptor in Prostate Cancer With (64)Cu-Labeled Neurotensin Analogs
por: Deng, Huaifu, et al.
Publicado: (2017)